Serveur d'exploration Tocilizumab - Analysis (2020)

Index « AbsEn.i » - entrée « adverse »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
advent < adverse < advice  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 37.
[0-20] [0 - 20][0 - 37][20-36][20-40]
Ident.Authors (with country if any)Title
000014 (2020) Puja Mehta ; Jessica J. MansonWhat Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?
000035 (2020) Limin Li [République populaire de Chine] ; Jie Liu [République populaire de Chine] ; Mengyuan Xu [République populaire de Chine] ; Hongjuan Yu [République populaire de Chine] ; Chengfang Lv [République populaire de Chine] ; Fenglin Cao [République populaire de Chine] ; Zhenkun Wang [République populaire de Chine] ; Yueyue Fu [République populaire de Chine] ; Mingwen Zhang [République populaire de Chine] ; Hongbin Meng [République populaire de Chine] ; Xiaoqian Zhang [République populaire de Chine] ; Liqing Kang [République populaire de Chine] ; Zhuo Zhang [République populaire de Chine] ; Jinmei Li [République populaire de Chine] ; Jiawei Feng [République populaire de Chine] ; Xin Lian [République populaire de Chine] ; Lei Yu [République populaire de Chine] ; Jin Zhou [République populaire de Chine]Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients
000036 (2020) B P Hibler [États-Unis] ; A. Markova [États-Unis]Treatment of severe cutaneous adverse reaction with tocilizumab.
000082 (2020) Eun-Jung Park [Corée du Sud] ; Hyungjin Kim [Corée du Sud] ; Seung Min Jung [Corée du Sud] ; Yoon-Kyoung Sung [Corée du Sud] ; Han Joo Baek [Corée du Sud] ; Jisoo Lee [Corée du Sud]The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus
000087 (2020) Wanhai Ke ; Li Zhang ; Yan DaiThe role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
000141 (2020) Adam Amlani [Canada] ; Claire Barber [Canada] ; Aurore Fifi-Mah [Canada] ; Jose Monzon [Canada]Successful Treatment of Cytokine Release Syndrome with IL-6 Blockade in a Patient Transitioning from Immune-Checkpoint to MEK/BRAF Inhibition: A Case Report and Review of Literature.
000155 (2020) Meng Xu ; Congcong Liu ; Lishuang Guo ; Sirui YangSevere sepsis caused by serious gastrointestinal infection in sJIA patients treated with IL-6 receptor antagonist: a case report
000169 (2020) Maria Antonietta Barbieri [Italie] ; Giuseppe Cicala [Italie] ; Paola Maria Cutroneo [Italie] ; Elisabetta Gerratana [Italie] ; Caterina Palleria [Italie] ; Caterina De Sarro [Italie] ; Ada Vero [Italie] ; Luigi Iannone [Italie] ; Antonia Manti [Italie] ; Emilio Russo [Italie] ; Giovambattista De Sarro [Italie] ; Fabiola Atzeni [Italie] ; Edoardo Spina [Italie]Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study.
000183 (2020) Ibai Los-Arcos [Espagne] ; Juan Aguilar-Company [Espagne] ; Isabel Ruiz-Camps [Espagne]Risk of infection associated with new therapies for lymphoproliferative syndromes.
000201 (2020) Naomi Serling-Boyd [États-Unis] ; John H. StoneRecent advances in the diagnosis and management of giant cell arteritis.
000206 (2020) Christos Koutsianas ; Konstantinos Thomas ; Dimitrios VassilopoulosReactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations
000208 (2020) Natalia Maximova [Italie] ; Alessandra Maestro [Italie] ; Davide Zanon [Italie] ; Annalisa Marcuzzi [Italie]Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration
000233 (2020) Giulia Cassone [Italie] ; Marco Sebastiani [Italie] ; Caterina Vacchi [Italie] ; Stefania Cerri [Italie] ; Carlo Salvarani [Italie] ; Andreina Manfredi [Italie]Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?
000240 (2020) James Kalmuk [États-Unis] ; Jon Puchalla [États-Unis] ; Gong Feng [États-Unis] ; Anshu Giri [États-Unis] ; John Kaczmar [États-Unis]Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge
000265 (2020) G. S. Braun [Allemagne] ; M. Kirschner [Allemagne] ; A. Rübben [Allemagne] ; R. U. Wahl [Allemagne] ; K. Amann [Allemagne] ; K. Benesova [Allemagne] ; J. Leipe [Allemagne]Nebenwirkungen neuer onkologischer Immuntherapien
000288 (2020) Xiaoyan Si ; Peng Song ; Jun Ni ; Mingyi Di ; Chunxia He ; Li Zhang ; Xiaowei Liu ; Yue Li ; Hanping Wang ; Xiaoxiao Guo ; Jiaxin Zhou ; Lian Duan ; Xu Yang ; Mengzhao Wang ; Li ZhangManagement of immune checkpoint inhibitor‐related adverse events: A review of case reports
000301 (2020) Austin R. Morrison ; Joseph M. Johnson ; Mayur Ramesh ; Patrick Bradley ; Jeffery Jennings ; Zachary R. SmithLetter to the Editor: Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab.
000330 (2020) Cécile Dumaine [France] ; Sara Bekkar [France] ; Alexandre Belot [France] ; Natalia Cabrera [France] ; Salma Malik [France] ; Annette Von Scheven [Suisse] ; Aurelia Carbasse [France] ; Andreas Woerner [Suisse] ; Carine Wouters [Belgique] ; Kenza Bouayed ; Pascal Pillet [France] ; Silke Schroeder [Suisse] ; Michael Hofer [Suisse] ; Véronique Hentgen [France]Infectious adverse events in children with Juvenile Idiopathic Arthritis treated with Biological Agents in a real-life setting: Data from the JIRcohorte.
000344 (2020) Sadaf Atiqi [Pays-Bas] ; Femke Hooijberg [Pays-Bas] ; Floris C. Loeff [Pays-Bas] ; Theo Rispens [Pays-Bas] ; Gerrit J. Wolbink [Pays-Bas]Immunogenicity of TNF-Inhibitors
000345 (2020) Immune-Related Adverse Events: Pneumonitis
000379 (2020) Jeremiah Au ; Frederick T. Gibson [États-Unis] ; Iris K. AronsonFollicular occlusion triad: an isotopic response or adverse effect of rituximab?

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i -k "adverse" 
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i  \
                -Sk "adverse" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    adverse
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021